🤔 What Is This Report? (Demo Scenario)
In this fictional demonstration, LumenArc Biomedical is a clinical-stage medical-device startup developing VistaFlex™ VF-200, an accommodating intraocular lens (IOL) implanted during cataract surgery. Before investing in a large pivotal trial, the company ran a small early feasibility study comparing two haptic designs — T1 (5° haptic angulation) and T2 (10° haptic angulation) — with each patient receiving one of each design, one per eye.
This report is the company's first look at interpretable results: is the lens sitting where it should (the primary “lens fit” question), is vision good, is it safe, and what should be decided before the next, bigger study? It follows the structure of a Master Feasibility Clinical Protocol (rationale → design → population → primary / secondary / exploratory effectiveness → subgroups → safety → device deficiencies → analysis plan).
Headline charts
Eight quick visuals — details and more on each tab
Subject funnel
Lens decentration over time (mm)
Fit grade at Month 1
Month-6 BCVA distribution
Adverse events by relationship
Readiness vs pivotal threshold
Summary forest — standardised within-subject difference (dz, T2 − T1), 95% CI
2.1 Study Rationale and Purpose
The VistaFlex™ VF-200 accommodating IOL is intended for the optical correction of aphakia following cataract removal in adults. The purpose of this early feasibility study is to obtain in-eye performance data to inform implant design lock ahead of a pivotal study. Results are not currently planned for publication, but may be offered if of scientific interest or if they relate to a product subsequently cleared for marketing.
2.2 Trial Objectives
Primary: evaluate lens fit (centration and tilt; optimal / acceptable fit rate) of two haptic angulations of a single-piece hydrophobic-acrylic accommodating IOL.
Key exploratory: assess optic surface performance (glistenings, deposits, posterior capsule opacification) through 6 months.
2.3 Risks and Benefits
There is no intended clinical benefit beyond that of standard cataract surgery with IOL implantation. Potential risks include corneal edema, intraocular inflammation, IOP elevation, lens decentration/tilt, posterior capsule opacification, cystoid macular edema and visual disturbances. Risks are minimized by eligibility criteria, standardized surgical technique and close supervision by a licensed surgeon.
2.4 Subject Population & 2.5 Outline
Approximately 44 volunteer subjects at 1 site (fictional: “Meridian Eye Institute”), bilateral age-related cataract, planned implantation of both eyes. Target: 36 completers.
Stage I — prospective, randomized, double-masked, contralateral-eye comparison of T1 vs T2 through Day 7. Stage II — open-label follow-up of all implanted eyes to Month 6. Up to 4 scheduled postoperative visits per eye.
Study flow
Visit schedule and stages
3.1 Identity of study treatments
Schedule of assessments
Endpoint hierarchy (Section 5.4)
Subject disposition
Cumulative enrollment by month
Subject disposition table
Screen-failure & discontinuation reasons
Demographics & baseline characteristics
Section 5.3 — summarized on the safety analysis set
Age distribution
Sex
Race
Axial length (mm)
Implanted IOL power (D)
Baseline BCVA (logMAR)
Baseline table
Analysis data sets
Visit attendance & window compliance
Data completeness by visit & domain (% of expected eyes)
Decentration over time (mm)
Tilt over time (°)
Fit grade by design — Month 1
Fit grade by design — Month 6
Distribution of decentration at Month 6
Cumulative % of eyes at or below decentration threshold (M6)
Paired eye-vs-eye decentration (M6)
Primary results table
Decentration — within-subject difference (T2 − T1), mm
Tilt — within-subject difference (T2 − T1), degrees
BCVA (logMAR) by visit — median & IQR
Cumulative BCVA at Month 6
Predicted vs achieved SEQ (D)
Refractive prediction error
% eyes within ±0.25 / ±0.50 / ±1.00 D
Defocus curve (logMAR)
Photopic contrast sensitivity
Patient-reported outcomes — Month 6 (T2 shown; T1 in table)
Visual symptom bother (0–4)
Secondary outcomes table
Posterior capsule opacification grade (M6)
Glistenings grade (M6)
Optic surface deposits — % eyes ≥ grade 1
Effective lens position / ACD shift (mm)
Endothelial cell density change (%)
Intraocular pressure (mmHg)
Anterior chamber flare (photons/ms)
Surgeon-rated handling (insertion & unfolding)
Lens unfolding time (seconds)
Exploratory outcomes table
Forest plot — within-subject difference in decentration (T2 − T1)
Mean decentration by axial-length tercile (M6)
Mean decentration by IOL power group (M6)
Optimal-fit rate by age group (M1)
Subgroup table
Figure 7-1 · Categorization of all AEs
Figure 7-2 · Categorization of serious adverse events
Ocular AEs by Preferred Term and design (events)
AE table (MedDRA PT)
Severity
Onset timing (days post-implant)
Outcome at last follow-up
Freedom from ocular AE (Kaplan–Meier style)
Biomicroscopy — eyes with ≥2-grade increase from baseline
Biomicroscopy findings ≥ grade 1 over time (% eyes)
Subjects with ≥1 AE, by category
Device deficiencies by category
Pre-exposure vs treatment-emergent
Device deficiency listing
Return product analysis (7.4)
Statistical analysis plan summary
Sensitivity — M6 decentration difference (T2 − T1)
Pivotal sample-size curves (paired design)
Precision: 95% CI half-width vs sample size
Sample size justification (5.10)
Protocol amendment history
✅ What the first interpretable results support
⚠️ What they cannot support yet
- Any claim of superiority, efficacy or safety — the study is not powered for inference.
- Generalisation beyond one fictional site, ~44 subjects and 6 months of follow-up.
- Long-term outcomes: PCO, glistenings and late decentration usually need 12–36 months.
- Reimbursement, manufacturing-at-scale or commercial conclusions.
Readiness scorecard (0–100)
Decision matrix
Roadmap — next 12 months (fictional)
Sequenced milestones from feasibility close-out to first pivotal enrolment
Risk register — top risks
Higgins acceleration playbook
Higgins AI — the Business Growth Accelerator
Higgins is positioned as a Business Growth Accelerator — an intelligent layer that sits in front of the software a company already uses. Instead of wrestling with menus, teams simply talk to Higgins, which handles the complexity behind the scenes while actively growing the business on two fronts.
S.A.L.E.s finds the best prospects (Sourcing the right clients, Assessing how they buy, Listening to their needs, and Empowering them to refer others). P.U.R.E.S. selects the single best one to approach first. P.I.T.C.H. identifies the best investor to fund the growth.
🎯 Growth Accelerator First
Built to grow revenue — sourcing the right clients, assessing how they buy, listening to their needs and empowering referrals.
🔗 Works With Existing Software
Sits on top of existing tools and makes them more valuable without replacing them — no rip-and-replace.
🛡️ Patent-protected technology
Patents: US9971979B2 and 63/794177. Higgins presents its technology as patented and licensed by large platform companies.
Figures as stated by Higgins on its About page
Company-reported; shown for context, not independently verified by this report
Businesses using Higgins
Avg. client ROI
Guaranteed min. ROI (Yr 1)
Market entered
Pre-seed SAFE round
Revenue growth (main product)
How S.A.L.E.s · P.U.R.E.S. · P.I.T.C.H. apply to a biomedical company
Where this report sits on the Innovation Highway
📬 Contact
Investor enquiries listed on the Higgins page: investor@higgins.ai · higgins.ai
Positive testimonials
Platform / product praise
Investment-related praise
Accelerator leader voices
Praise by topic (all 205)
Who is speaking
Biomedical & accelerator voices
Verbatim excerpts from client meetings, lightly trimmed
“…you have the potential to kind of create an ecosystem, right? … you can start to merge these ecosystems and kind of say, where is the alignment between the bank and the pharma company, or whoever, right? And get the intelligence that…”
“That is incredibly helpful, because I think one of the hardest things is… knowing where to go and who to talk to.”
“Yeah, this diligence room was set up with Higgins, and, you know, so there's a certain level of credibility to it, and then you could probably sell it to the investors, so they could say, diligence these guys.”
“I think it's who would take advantage of this the most, right at this point in time.”
“Well, I enjoyed this. I'll race this up the flagpole… and maybe we may have some more questions or want to meet again.”
“Does HAL do those kinds of cap table analysis and stuff like that? Awesome. Awesome. Okay, wow.”
“…it would be great if we could chat again… you've given me a lot to think about.”
Why this matters for biomedical companies
Feasibility data only creates value when the right investors, strategic partners and clinical sites see it in a credible, diligence-ready form. Biotech and accelerator voices above point to the same needs this report addresses: knowing who to talk to, a credible data room, and cap-table / investor intelligence.
Important disclaimer
This is a demonstration document. LumenArc Biomedical, Inc., VistaFlex™, the VF-200 accommodating intraocular lens, Study LAB-VF-EFS-001, “Meridian Eye Institute”, all subjects, investigators, sites, adverse events, device deficiencies, financial and readiness figures are entirely fictional. Any resemblance to real companies, products, studies or persons is coincidental. All results were generated synthetically by a pseudo-random process to show what a Higgins Reports Clinical First Interpretable Results dashboard looks like.
This report is not clinical evidence, not a regulatory submission, not medical advice, and not investment, legal or financial advice. No conclusion in it should be relied on for any clinical, regulatory or investment decision. “Higgins About” and “Testimonials” sections reflect content published by Higgins and are included for context; figures there are company-reported and not independently verified.
How the synthetic data were generated
- 44 enrolled subjects; 42 bilaterally implanted (84 eyes); 39 completed Month 6.
- Each subject receives T1 in one eye and T2 in the other (randomized, masked).
- Outcomes are drawn from distributions with a subject-level random effect so paired analyses behave realistically; seed fixed so the report is reproducible.
- Summary statistics, tables and charts on every tab are computed from the same synthetic subject-level dataset (except where noted, e.g. small AE count tables, which are fixed fictional listings).
- Confidence intervals use a t-approximation and are descriptive; no p-values are presented.
Template & structure
Section structure follows a Master Feasibility Clinical Protocol template (Introduction, Treatments, Study Procedures, Analysis Plan, Adverse Events & Device Deficiencies, Confidentiality, Data Handling, Ethics, Amendment History). The template's contact-lens specifics were adapted to a fictional implantable device.
Visual styling follows the Higgins Reports Innovation Highway dashboard format.